168 related articles for article (PubMed ID: 20677538)
1. Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders.
Ladizinski B; Shannon EJ; Sanchez MR; Levis WR
J Drugs Dermatol; 2010 Jul; 9(7):814-26. PubMed ID: 20677538
[TBL] [Abstract][Full Text] [Related]
2. The potential of immunomodulatory drugs in the treatment of solid tumors.
Dalgleish A; Galustian C
Future Oncol; 2010 Sep; 6(9):1479-84. PubMed ID: 20919830
[TBL] [Abstract][Full Text] [Related]
3. A review of thalidomide's history and current dermatological applications.
Perri AJ; Hsu S
Dermatol Online J; 2003 Aug; 9(3):5. PubMed ID: 12952752
[TBL] [Abstract][Full Text] [Related]
4. IMiDs: a novel class of immunomodulators.
Knight R
Semin Oncol; 2005 Aug; 32(4 Suppl 5):S24-30. PubMed ID: 16085014
[TBL] [Abstract][Full Text] [Related]
5. Thalidomide: an experience in therapeutic outcome and adverse reactions.
Sharma NL; Sharma VC; Mahajan VK; Shanker V; Ranjan N; Gupta M
J Dermatolog Treat; 2007; 18(6):335-40. PubMed ID: 17852637
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy.
Shortt J; Hsu AK; Johnstone RW
Oncogene; 2013 Sep; 32(36):4191-202. PubMed ID: 23318436
[TBL] [Abstract][Full Text] [Related]
7. Thalidomide--effect on T cell subsets as a possible mechanism of action.
Moncada B; Baranda ML; González-Amaro R; Urbina R; Loredo CE
Int J Lepr Other Mycobact Dis; 1985 Jun; 53(2):201-5. PubMed ID: 3874920
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide and lenalidomide in the treatment of multiple myeloma.
Kumar S; Rajkumar SV
Eur J Cancer; 2006 Jul; 42(11):1612-22. PubMed ID: 16750621
[TBL] [Abstract][Full Text] [Related]
9. Thalidomide in leprosy and some dermatological conditions--a review.
Parikh DA; Maniar JK; Ganapati R
Indian J Lepr; 1985; 57(4):862-7. PubMed ID: 3915010
[No Abstract] [Full Text] [Related]
10. Immunomodulatory drugs in the treatment of myelodysplastic syndromes.
Ortega J; List A
Curr Opin Oncol; 2007 Nov; 19(6):656-9. PubMed ID: 17906467
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide and its dermatologic uses.
Moraes M; Russo G
Am J Med Sci; 2001 May; 321(5):321-6. PubMed ID: 11370795
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide: current and potential clinical applications.
Calabrese L; Fleischer AB
Am J Med; 2000 Apr; 108(6):487-95. PubMed ID: 10781782
[TBL] [Abstract][Full Text] [Related]
13. Recent advances of IMiDs in cancer therapy.
Li S; Gill N; Lentzsch S
Curr Opin Oncol; 2010 Nov; 22(6):579-85. PubMed ID: 20689431
[TBL] [Abstract][Full Text] [Related]
14. The thalidomide saga.
Melchert M; List A
Int J Biochem Cell Biol; 2007; 39(7-8):1489-99. PubMed ID: 17369076
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide: dermatological indications, mechanisms of action and side-effects.
Wu JJ; Huang DB; Pang KR; Hsu S; Tyring SK
Br J Dermatol; 2005 Aug; 153(2):254-73. PubMed ID: 16086735
[TBL] [Abstract][Full Text] [Related]
16. Innovative uses of thalidomide.
Chen M; Doherty SD; Hsu S
Dermatol Clin; 2010 Jul; 28(3):577-86. PubMed ID: 20510766
[TBL] [Abstract][Full Text] [Related]
17. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide as a novel therapeutic agent: new uses for an old product.
Teo SK; Stirling DI; Zeldis JB
Drug Discov Today; 2005 Jan; 10(2):107-14. PubMed ID: 15718159
[TBL] [Abstract][Full Text] [Related]
19. Immunomodulatory drugs.
Crane E; List A
Cancer Invest; 2005; 23(7):625-34. PubMed ID: 16305990
[TBL] [Abstract][Full Text] [Related]
20. Thalidomide: mechanisms of action.
Paravar T; Lee DJ
Int Rev Immunol; 2008; 27(3):111-35. PubMed ID: 18437602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
